Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gene-Editing Technology May Produce Resistant Virus in Cassava Plant

By University of Alberta | April 26, 2019

The use of gene-editing technology to create virus-resistant cassava plants could have serious negative ramifications, according to new research by plant biologists at the University of Alberta, the University of Liege in Belgium, and the Swiss Federal Institute of Technology. Their results show that attempts to genetically engineer the plants to fight off viruses, in fact resulted in the propagation of mutated viruses in controlled laboratory conditions.

“We concluded that because this technology both creates a selection pressure on the viruses to evolve more quickly, and also provides the viruses a means to evolve, it resulted in a virus mutant that is resistant to our interventions,” explained Devang Mehta, postdoctoral fellow in the Department of Biological Sciences. CRISPR-Cas9 is found in nature, where bacteria use it to defend against viruses, however the researchers found that the technology results in very different outcomes in plants–and researchers are stressing the importance of screening against these sorts of unintended results in the future.

The cassava plant, the object of the study, is a starchy root vegetable that is consumed for food throughout the tropics. Cassava is a primary staple crop grown in South America, Africa, and Asia, from which 1 billion people get most of their calories each day. Each year, cassava crops are plagued by cassava mosaic disease, which causes 20 per cent crop loss. It is the mosaic disease that Mehta and his colleagues endeavoured to engineer against.

The researchers used a new gene-editing technology called CRISPR-Cas9 to attempt to design cassava plants that could cut the DNA of the mosaic virus and make the plants resistant to its damaging effects. Unfortunately, their results were not successful. To understand what happened, the team sequenced hundreds of viral genomes found in each plant.

“We discovered that the pressure that CRISPR-Cas9 applied to the virus probably encouraged it to evolve in a way that increased resistance to intervention,” said Mehta. Mehta hastens to add that CRISPR-Cas9 has many other applications in food and agriculture that do not pose the same risks.

The research team is keen to share their results with other scientists who are using CRISPR-Cas9 technology to engineer virus-resistant plants, and encourage these groups to test their plants to detect similar viral mutations.

“We need to do more research on these types of applications of CRISPR-Cas9 technology before we proceed with field testing” said Mehta. Mehta, a postdoctoral fellow with Professor Glen Uhrig, began this research during his PhD studies at the Swiss Federal Institute of Technology (ETH) in Zurich.


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE